PubMed COVID-19 Clinical Care
5611 - 5620 of 44979 results found
Resiliency and Mental Health in the Intensive Care Unit
Description
No abstract
Definitional and Methodological Study of Pediatric Post-COVID-19 Condition-Reply
Description
No abstract
Remote hearing-aid delivery and support: perspectives of patients and their hearing care providers
Description
CONCLUSIONS: Patients were generally highly satisfied with the service and for 1 in 3 it was their preferred mode of future hearing-aid fitting. Future services should be aware that a one-size-fits-all approach will not satisfy all patients and that
Profiling of Surface Protein Epitopes on Viral Particles by Multiplex Dual-Reporter Strategy
Description
Membrane proteins on enveloped viruses play an important role in many biological functions involving virus attachment to target cell receptors, fusion of viral particles to host cells, host-virus interactions, and disease pathogenesis. Furthermore
Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators
Description
CONCLUSIONS: This study identified key barriers and facilitators that OICs may consider as this model expands in the United States. Referral to and engagement in OUD treatment within the OIC context requires ongoing efforts to bridge the treatment
Emergence and spread of SARS-CoV-2 variants of concern in Canada: a retrospective analysis from clinical and wastewater data
Description
CONCLUSION: In particular, it took approximately four months for VOC Alpha and Delta to contribute to half of the incidence. In contrast, VOC Omicron achieved the same contribution in less than one month. This study provides significant benchmarks to
Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study
Description
ChulaCov19 mRNA vaccine demonstrated promising phase 1 results. Healthy adults aged 18-59 years were double-blind randomised 4:1 to receive two intramuscular doses of ChulaCov19 50 µg or placebo. Primary endpoints were safety and microneutralization
